Erdafitinib for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor

  • Technology appraisal guidance
  • TA1062
  • Published: 

Evidence

Documents containing the evidence that was used to develop the recommendations.

Supporting evidence